A citation-based method for searching scientific literature

Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021
Times Cited: 9







List of co-cited articles
87 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Sylvie M Noordermeer, Haico van Attikum. Trends Cell Biol 2019
113
44

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
44

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
44

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Harveer Dev, Ting-Wei Will Chiang, Chloe Lescale, Inge de Krijger, Alistair G Martin, Domenic Pilger, Julia Coates, Matylda Sczaniecka-Clift, Wenming Wei, Matthias Ostermaier,[...]. Nat Cell Biol 2018
145
44

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Janneke E Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly,[...]. Cancer Discov 2013
302
33

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, Y H Ibrahim, A Gris-Oliver, S Bonache, B Morancho, A Bruna, O M Rueda,[...]. Ann Oncol 2018
134
33

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
929
33

Replication fork stability confers chemoresistance in BRCA-deficient cells.
Arnab Ray Chaudhuri, Elsa Callen, Xia Ding, Ewa Gogola, Alexandra A Duarte, Ji-Eun Lee, Nancy Wong, Vanessa Lafarga, Jennifer A Calvo, Nicholas J Panzarino,[...]. Nature 2016
401
33

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.
Arnab Ray Chaudhuri, André Nussenzweig. Nat Rev Mol Cell Biol 2017
464
33


Isomerization of BRCA1-BARD1 promotes replication fork protection.
Manuel Daza-Martin, Katarzyna Starowicz, Mohammed Jamshad, Stephanie Tye, George E Ronson, Hannah L MacKay, Anoop Singh Chauhan, Alexandra K Walker, Helen R Stone, James F J Beesley,[...]. Nature 2019
41
33

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Aubrey L Miller, Samuel C Fehling, Patrick L Garcia, Tracy L Gamblin, Leona N Council, Robert C A M van Waardenburg, Eddy S Yang, James E Bradner, Karina J Yoon. EBioMedicine 2019
39
33

Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Rohit Prakash, Yu Zhang, Weiran Feng, Maria Jasin. Cold Spring Harb Perspect Biol 2015
373
33

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
405
33


CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Michal Zimmermann, Olga Murina, Martin A M Reijns, Angelo Agathanggelou, Rachel Challis, Žygimantė Tarnauskaitė, Morwenna Muir, Adeline Fluteau, Michael Aregger, Andrea McEwan,[...]. Nature 2018
142
22

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
A G Waks, O Cohen, B Kochupurakkal, D Kim, C E Dunn, J Buendia Buendia, S Wander, K Helvie, M R Lloyd, L Marini,[...]. Ann Oncol 2020
41
22

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
300
22

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Junko Murai, Ying Feng, Guoying K Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves Pommier. Oncotarget 2016
131
22

Mechanisms of DNA damage, repair, and mutagenesis.
Nimrat Chatterjee, Graham C Walker. Environ Mol Mutagen 2017
383
22

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
116
22

High speed of fork progression induces DNA replication stress and genomic instability.
Apolinar Maya-Mendoza, Pavel Moudry, Joanna Maria Merchut-Maya, MyungHee Lee, Robert Strauss, Jiri Bartek. Nature 2018
180
22

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
H P Eikesdal, S Yndestad, A Elzawahry, A Llop-Guevara, B Gilje, E S Blix, H Espelid, S Lundgren, J Geisler, G Vagstad,[...]. Ann Oncol 2021
18
22

PARP inhibitor resistance: the underlying mechanisms and clinical implications.
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang. Mol Cancer 2020
42
22

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Raphael Ceccaldi, Jessica C Liu, Ravindra Amunugama, Ildiko Hajdu, Benjamin Primack, Mark I R Petalcorin, Kevin W O'Connor, Panagiotis A Konstantinopoulos, Stephen J Elledge, Simon J Boulton,[...]. Nature 2015
394
22

A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
Jia Zhou, Camille Gelot, Constantia Pantelidou, Adam Li, Hatice Yücel, Rachel E Davis, Anniina Farkkila, Bose Kochupurakkal, Aleem Syed, Geoffrey I Shapiro,[...]. Nat Cancer 2021
17
22

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
Priyanka Verma, Yeqiao Zhou, Zhendong Cao, Peter V Deraska, Moniher Deb, Eri Arai, Weihua Li, Yue Shao, Laura Puentes, Yiwen Li,[...]. Nat Cell Biol 2021
26
22


EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
Beatrice Rondinelli, Ewa Gogola, Hatice Yücel, Alexandra A Duarte, Marieke van de Ven, Roxanne van der Sluijs, Panagiotis A Konstantinopoulos, Jos Jonkers, Raphaël Ceccaldi, Sven Rottenberg,[...]. Nat Cell Biol 2017
157
22

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Ewa Gogola, Alexandra A Duarte, Julian R de Ruiter, Wouter W Wiegant, Jonas A Schmid, Roebi de Bruijn, Dominic I James, Sergi Guerrero Llobet, Daniel J Vis, Stefano Annunziato,[...]. Cancer Cell 2018
111
22

Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease.
Evgeniia Prokhorova, Thomas Agnew, Anne R Wondisford, Michael Tellier, Nicole Kaminski, Danique Beijer, James Holder, Josephine Groslambert, Marcin J Suskiewicz, Kang Zhu,[...]. Mol Cell 2021
13
22

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Stephen J Pettitt, Dragomir B Krastev, Inger Brandsma, Amy Dréan, Feifei Song, Radoslav Aleksandrov, Maria I Harrell, Malini Menon, Rachel Brough, James Campbell,[...]. Nat Commun 2018
147
22

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Ke Cong, Min Peng, Arne Nedergaard Kousholt, Wei Ting C Lee, Silviana Lee, Sumeet Nayak, John Krais, Pamela S VanderVere-Carozza, Katherine S Pawelczak, Jennifer Calvo,[...]. Mol Cell 2021
10
22

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.
Raffaella Casolino, Salvatore Paiella, Danila Azzolina, Philip A Beer, Vincenzo Corbo, Giulia Lorenzoni, Dario Gregori, Talia Golan, Chiara Braconi, Fieke E M Froeling,[...]. J Clin Oncol 2021
3
66

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.
Katharina Schlacher, Nicole Christ, Nicolas Siaud, Akinori Egashira, Hong Wu, Maria Jasin. Cell 2011
719
22

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B Baylin, Daniela Matei, Harikrishna Nakshatri,[...]. Clin Cancer Res 2018
49
22

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Max M Wattenberg, Daniella Asch, Shun Yu, Peter J O'Dwyer, Susan M Domchek, Katherine L Nathanson, Mark A Rosen, Gregory L Beatty, Evan S Siegelman, Kim A Reiss. Br J Cancer 2020
48
22

Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Lu Yang, Youyou Zhang, Weiwei Shan, Zhongyi Hu, Jiao Yuan, Jingjiang Pi, Yueying Wang, Lingling Fan, Zhaoqing Tang, Chunsheng Li,[...]. Sci Transl Med 2017
103
22

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Daniel D Von Hoff, Thomas Ervin, Francis P Arena, E Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A Tjulandin, Wen Wee Ma, Mansoor N Saleh,[...]. N Engl J Med 2013
22

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
171
22

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
T Golan, Z S Kanji, R Epelbaum, N Devaud, E Dagan, S Holter, D Aderka, S Paluch-Shimon, B Kaufman, R Gershoni-Baruch,[...]. Br J Cancer 2014
212
22

PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
Shirley M H Sy, Michael S Y Huen, Junjie Chen. Proc Natl Acad Sci U S A 2009
350
22

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
633
22

The repertoire of mutational signatures in human cancer.
Ludmil B Alexandrov, Jaegil Kim, Nicholas J Haradhvala, Mi Ni Huang, Alvin Wei Tian Ng, Yang Wu, Arnoud Boot, Kyle R Covington, Dmitry A Gordenin, Erik N Bergstrom,[...]. Nature 2020
594
22

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Aparajitha Vaidyanathan, Lynne Sawers, Anne-Louise Gannon, Probir Chakravarty, Alison L Scott, Susan E Bray, Michelle J Ferguson, Gillian Smith. Br J Cancer 2016
136
22

Repair of strand breaks by homologous recombination.
Maria Jasin, Rodney Rothstein. Cold Spring Harb Perspect Biol 2013
465
22

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Talia Golan, Grainne M O'Kane, Robert E Denroche, Maria Raitses-Gurevich, Robert C Grant, Spring Holter, Yifan Wang, Amy Zhang, Gun Ho Jang, Chani Stossel,[...]. Gastroenterology 2021
20
22

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Milind Javle, Einat Shacham-Shmueli, Lianchun Xiao, Gauri Varadhachary, Naama Halpern, David Fogelman, Ben Boursi, Syeda Uruba, Ofer Margalit, Robert A Wolff,[...]. JAMA Oncol 2021
14
22

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
585
22



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.